Skip To Content

Study ID: Bayer Janssen BAY 59-7939 / 17454 Xaralto VOYAGER PAD Study

Title:

An international, multicenter, randomized, double-blind, placebocontrolled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

Location:
Sioux Falls Region
Principal Investigator:
Angelo Santos, MD
Disease:
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.